while preliminary screening for interactions between new cardiovascular pharmacotherapeutic agents and digoxin can be efficiently and safely conducted in normal healthy volunteers , it is particularly important to detect and quantify drug interactions in patients with varying degrees of cardiac , hepatic and/or renal dysfunction .
C0007226
cardiovascular
C0018787
cardiac